Alcon Inc. (ALC) News
Follow Alcon Inc. (ALC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Algoma Central Third-Quarter Profit Jumps on Strong Bulk Demand
Algoma Central reported higher third-quarter profit, citing strong agricultural and construction shipping volumes, expanded fleet capacity and a gain from selling two vessels. The body is truncated before the reported ne
EARNINGS | Nov 06, 2026, 02:35 PM UTC
M
Algoma Central reports third-quarter revenue of C$287,751
EQUITY | Nov 06, 2026, 12:05 PM UTC
M
Algoma Central Closes $70 Million Convertible Debenture Financing
Algoma Central closed its previously announced offering of $70 million in 6.20% convertible unsecured subordinated debentures, priced at $1,000 each.
EQUITY | Nov 04, 2026, 01:55 PM UTC
M
Algoma Central Underwriters to Purchase $70 Million of 6.20% Convertible Debentures
EQUITY | Oct 21, 2026, 02:37 PM UTC
M
Algoma Central Upsizes Convertible Debenture Offering to $70M
Algoma Central increased its bought deal to $70 million of 6.20% convertible debentures, including a $10.5 million over-allotment, and a concurrent $20 million private placement to E—L. The debentures mature Dec. 31, 203
EQUITY | Oct 21, 2026, 01:38 PM UTC
M
Alcon Acquires Neurotech and Encelto, an FDA-Approved MacTel Type 2 Treatment
EQUITY | Oct 20, 2026, 10:02 PM UTC
L
Algoma Central Announces $62.5 Million Debenture Offering
Algoma Central announced an offering of $62.5 million of 6.20% convertible unsecured subordinated debentures.
EQUITY | Oct 20, 2026, 10:01 PM UTC
M
Alcon acquires Neurotech Pharmaceuticals
EQUITY | Oct 20, 2026, 08:36 PM UTC
M
Algoma Central Announces Convertible Debenture Offering
Algoma Central announced an agreement to sell 6.20% convertible unsecured subordinated debentures on a bought-deal basis.
EQUITY | Oct 20, 2026, 08:34 PM UTC
M
Alcon Wins FDA Approval for Brytly Eye Drops
Alcon said it expects to make the eye drops available for retail and online shopping in the coming months, with future expansion into additional markets.
REGULATION | Oct 16, 2026, 08:12 PM UTC
L
Alcidion Group Signed A New Contract With Northern Care Alliance NHS Foundation Trust
Alcidion Group Ltd ASX:ALC
NEWS | Sep 30, 2026, 01:37 AM UTC
L
Alcon offering expected to close Sept 2
Alcon says its offering is expected to close on Sept 2.
EQUITY | Aug 26, 2026, 09:03 PM UTC
L
Alcon AG prices EUR 500 million 3.875% notes due 2033
Alcon AG priced EUR 500 million 3.875% senior notes due 2033.
EQUITY | Aug 26, 2026, 09:01 PM UTC
L
Alcon prices EUR 500 million senior notes offering
Alcon has priced a EUR 500 million senior notes offering.
EQUITY | Aug 26, 2026, 09:00 PM UTC
L
Alcon Raises FY2026 Adj EPS Guidance from $3.38-$3.47 to $3.44-$3.53 vs $3.41 Est; Widens FY2026 Sales Guidance of $10.835B-$11.041B vs $11.
Alcon (NYSE: ALC ) raises FY2026 Adj EPS guidance from $3.38-$3.47 to $3.44-$3.53 vs $3.41 analyst estimate. Widens FY2026 sales outlook from $10.835 billion-$11.041 billion to $10.835 billion-$11.041 billion vs $11.087
EARNINGS | Aug 10, 2026, 08:32 PM UTC
H
S&P 500 Surges To Record Close Following Jobs Data: Investor Sentiment Improves, Fear Index Remains in ‘Greed’ Zone
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the “Greed” zone on Friday. U.S. stocks settled higher on Friday, with the Nasdaq Composite gaining mo
EARNINGS | Aug 10, 2026, 07:37 AM UTC
M
ALC Sees Improving Trends
ALC sees improving trends in contact lenses
EQUITY | Jul 29, 2026, 12:15 PM UTC